Clinical Trials Logo

Relapsed Small Cell Lung Cancer clinical trials

View clinical trials related to Relapsed Small Cell Lung Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06128837 Recruiting - Clinical trials for Relapsed Small Cell Lung Cancer

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Start date: March 3, 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter,randomized, open label, active-controlled, parallel-group study comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)

NCT ID: NCT05153239 Recruiting - Clinical trials for Relapsed Small Cell Lung Cancer

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Start date: July 22, 2022
Phase: Phase 3
Study type: Interventional

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

NCT ID: NCT04757779 Recruiting - Anlotinib Clinical Trials

A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

Start date: December 30, 2019
Phase: Phase 2
Study type: Interventional

Anlotinib hydrochloride is a multi-target antiangiogenic drug. It was recommended by Chinese Society of Clinical Oncology(CSCO) guideline as a third-line treatment for advanced small-cell lung cancer. This study intends to assess the efficacy and safety of anlotinib hydrochloride combined with irinotecan or docetaxel for second line treatment of nonsensitive relapsed small-cell lung cancer.